or Try an Advanced Search...

    Technical Analysis for VRNA - Verona Pharma plc

    Grade Last Price % Change Price Change
    F 14.79 -1.07% -0.16
    VRNA closed down 1.07 percent on Tuesday, May 7, 2024, on 78 percent of normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical VRNA trend table...
    Date Alert Name Type % Chg
    Earnings Movers Other 0.00%
    BB Squeeze Ended Range Expansion 0.00%
    Gapped Up Strength 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    MACD Bearish Signal Line Cross Bearish -1.07%
    Bollinger Band Squeeze Range Contraction -1.07%
    BB Squeeze + Lower Band Touch Range Contraction -1.07%
    BB Squeeze Started Range Contraction -1.07%
    Older End-of-Day Signals for VRNA ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 14 hours ago
    60 Minute Opening Range Breakdown about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    Down 1% about 15 hours ago
    Fell Below Lower Bollinger Band about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    VRNA Chart by TradingView
    Basic chart:

    Profile

    Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company's lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Asthma Respiratory Therapy Chronic Obstructive Pulmonary Disease Respiratory Diseases Cystic Fibrosis Phosphodiesterase Lung Disorders

    Is VRNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 2 Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
    Apr 25 Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
    Mar 4 Andrew Fisher Joins Verona Pharma as General Counsel
    Mar 1 Verona Pharma plc (NASDAQ:VRNA) Q4 2023 Earnings Call Transcript
    Mar 1 3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
    Feb 29 Verona Pharma plc (VRNA) Q4 2023 Earnings Call Transcript
    Feb 29 Verona Pharma plc 2023 Q4 - Results - Earnings Call Presentation
    Feb 29 Verona Pharma PLC Reports Fourth Quarter and Full Year 2023 Financial Results
    Feb 29 Earnings Scheduled For February 29, 2024
    Feb 29 Verona Pharma Non-GAAP EPS of -$0.02
    See more VRNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 23.81
    52 Week Low 11.83
    Average Volume 415,172
    200-Day Moving Average 16.67
    50-Day Moving Average 16.13
    20-Day Moving Average 15.67
    10-Day Moving Average 15.34
    Average True Range 0.60
    RSI (14) 36.31
    ADX 15.86
    +DI 12.38
    -DI 25.79
    Chandelier Exit (Long, 3 ATRs) 15.37
    Chandelier Exit (Short, 3 ATRs) 16.39
    Upper Bollinger Bands 16.52
    Lower Bollinger Band 14.82
    Percent B (%b) -0.02
    BandWidth 10.85
    MACD Line -0.30
    MACD Signal Line -0.24
    MACD Histogram -0.0528
    Fundamentals Value
    Market Cap 1.18 Billion
    Num Shares 79.9 Million
    EPS -0.56
    Price-to-Earnings (P/E) Ratio -26.41
    Price-to-Sales 2981.17
    Price-to-Book 5.16
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 15.62
    Resistance 3 (R3) 15.64 15.40 15.48
    Resistance 2 (R2) 15.40 15.19 15.38 15.43
    Resistance 1 (R1) 15.09 15.06 14.97 15.07 15.39
    Pivot Point 14.85 14.85 14.79 14.83 14.85
    Support 1 (S1) 14.54 14.64 14.42 14.52 14.19
    Support 2 (S2) 14.30 14.51 14.28 14.15
    Support 3 (S3) 13.99 14.30 14.10
    Support 4 (S4) 13.97